跳至主要内容
临床试验/NCT06818721
NCT06818721尚未招募2 期

Intravitreal Topotecan for the Prevention or Treatment of Proliferative Vitreoretinopathy in Patients with Rhegmatogenous Retinal Detachment: a Prospective Matched Cohort Study

Unity Health Toronto2 个研究点 分布在 1 个国家目标入组 394 人开始时间: 2025年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
尚未招募
入组人数
394
试验地点
2
主要终点
Rate of recurrent rhegmatogenous retinal detachment secondary to proliferative vitreoretinopathy

研究概览

简要总结

Intravitreal topotecan exhibits strong anti-inflammatory, anti-proliferative, and anti-fibrotic properties, making it a promising option for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Preclinical studies have demonstrated its efficacy in proliferative vitreoretinopathy models, where no adverse events have been reported for doses of 5 µg to 30 µg. This prospective, matched cohort study aims to assess the therapeutic efficacy and safety of intravitreal topotecan for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal detachment patients.

详细描述

Patients who provide informed consent for participation in the experimental study arm will undergo standard-of-care retinal detachment surgery with intravitreal topotecan (8 µg/0.05 mL), diluted in sterile saline and administered preoperatively within one week before surgery, as well as one week postoperatively. Matched historical control patients who received standard-of-care retinal detachment surgery without intravitreal topotecan will be eligible for study participation. Both the experimental and historical control study arms will be further divided into two groups: (i) patients with rhegmatogenous retinal detachment who exhibit high-risk characteristics of proliferative vitreoretinopathy on optical coherence tomography or have early proliferative vitreoretinopathy confirmed by clinical examination, and (ii) patients with rhegmatogenous retinal detachment who have neither high-risk characteristics of proliferative vitreoretinopathy nor a history of proliferative vitreoretinopathy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 18 years and older
  • Patients who undergo pneumatic retinopexy, pars plana vitrectomy and/or scleral buckling for rhegmatogenous retinal detachment
  • Patients who are voluntarily able and willing to participate
  • Patients undergoing combined phacoemulsification and pars plana vitrectomy and/or scleral buckling will also be included. Any surgical technique will be considered, including relaxing retinotomy or retinectomy during pars plana vitrectomy.

排除标准

  • Patients with a history of exudative retinal detachment
  • Patients with severe non-proliferative or proliferative diabetic retinopathy
  • Patients with other planned ocular surgery following pars plana vitrectomy
  • Female patients of childbearing age (i.e. less than 50 years old) who intend to become pregnant over the course of the study
  • Patients with pre-existing bone marrow suppression or cytopenias
  • Patients with pre-existing interstitial lung disease

研究组 & 干预措施

Intravitreal topotecan with retinal detachment surgery

Experimental

Intravitreal topotecan 8 µg/0.05mL, diluted in sterile saline and administered preoperatively, within one week prior to surgery, as well as one week postoperatively.

干预措施: Intravitreal topotecan (Drug)

Intravitreal topotecan with retinal detachment surgery

Experimental

Intravitreal topotecan 8 µg/0.05mL, diluted in sterile saline and administered preoperatively, within one week prior to surgery, as well as one week postoperatively.

干预措施: Retinal detachment surgery (Procedure)

Retinal detachment surgery

Active Comparator

Historical control patients who previously received standard of care surgery for rhegmatogenous retinal detachment without intravitreal topotecan.

干预措施: Retinal detachment surgery (Procedure)

结局指标

主要结局

Rate of recurrent rhegmatogenous retinal detachment secondary to proliferative vitreoretinopathy

时间窗: 6 months or last follow-up

次要结局

  • Grade of proliferative vitreoretinopathy(6 months or last follow-up)
  • Rate of primary retinal reattachment(6 months or last follow-up)
  • Rate of final retinal reattachment(6 months or last follow-up)
  • Best-corrected visual acuity(6 months or last follow-up)
  • Change in best-corrected visual acuity from baseline(6 months or last follow-up)
  • Rate of complications(6 months or last follow-up)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验